Filana Therapeutics (FRA:PX91) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PX91 Filana Therapeutics Inc FRA:PX91
26 GF Score
Price €0.62
! 1 Warning Sign
View Full Analysis

What is Filana Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Filana Therapeutics  (FRA:PX91) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Filana Therapeutics Cyclically Adjusted PB Ratio Related Terms


Filana Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Cyclically Adjusted PB Ratio Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.51 6.87 5.75 0.71 0.61

Filana Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.75 0.58 0.45 0.34

FRA:PX91 vs EDSA, GRCE, VERU: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Filana Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:PX91
26GF Score
Filana Therapeutics Inc FRA:PX91
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Filana Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Filana Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.152/333.9520*333.9520
=1.152

Current CPI (Jun. 2026) = 333.9520.

Filana Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.742 241.428 3.793
201612 2.681 241.432 3.708
201703 2.372 243.801 3.249
201706 1.764 244.955 2.405
201709 1.458 246.819 1.973
201712 1.225 246.524 1.659
201803 1.215 249.554 1.626
201806 1.062 251.989 1.407
201809 0.999 252.439 1.322
201812 0.997 251.233 1.325
201903 0.960 254.202 1.261
201906 0.909 256.143 1.185
201909 0.929 256.759 1.208
201912 0.901 256.974 1.171
202003 0.915 258.115 1.184
202006 0.864 257.797 1.119
202009 0.799 260.280 1.025
202012 2.138 260.474 2.741
202103 5.980 264.877 7.539
202106 5.827 271.696 7.162
202109 5.769 274.310 7.023
202112 5.580 278.802 6.684
202203 5.323 287.504 6.183
202206 5.209 296.311 5.871
202209 5.064 296.808 5.698
202212 5.108 296.797 5.747
202303 4.498 301.836 4.977
202306 3.922 305.109 4.293
202309 3.478 307.789 3.774
202312 2.946 306.746 3.207
202403 1.683 312.332 1.799
202406 3.675 314.175 3.906
202409 3.112 315.301 3.296
202412 2.919 315.605 3.089
202503 2.446 319.799 2.554
202506 1.551 322.561 1.606
202509 1.437 324.800 1.477
202512 1.311 324.054 1.351
202603 1.224 330.213 1.238
202606 1.152 333.952 1.152

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Filana Therapeutics Business Description

Other Exchanges FLNA:USAFLNA:Mexico
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
26GF Score

Get the complete analysis for FRA:PX91

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price